InflaRX N.V.
- BID
1.575
- ASK
1.633
- 12,698 Units2,308 Units
- 07/22, 11:34:23 AM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
121.85%
Market Cap
236.26 Mil.
P/E Ratio
0.00
Dividend Yield
0.00 %
Earnings per Share
-0.68 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 1.575 G | 0 Units |
| PRICE DETERMINATION TIME | 07/22/2026 / 11:31:56 AM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 1.575 | 1.546 |
| PREV. DAY'S PRICE | 1.604 | (07/21) |
| CHANGE DAY BEFORE | -0.03 | -1.81 % |
| 52 WEEK HIGH / LOW | 2.434 (05/26) | 0.65 (02/12) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | -0.78 | -0.78 | -0.68 | -1.17 | -2.00 |
DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | - | 0.00 |
DIVIDEND YIELD IN % | 0.00 % | 0.00 % | 0.00 % | - | - |
DIVIDEND GROWTH IN % | - | - | - | - | - |
PRICE - EARNINGS RATIO | - | - | - | - | - |
PRICE - BOOK RATIO | 0.85 | 2.31 | 1.50 | - | - |
PRICE - SALES RATIO | 1,312.96 | 811.52 | 2,053.06 | - | - |
PRICE - CASH FLOW RATIO | - | - | - | - | - |
Master Data
| WKN | A2H7A5 |
| ISIN | NL0012661870 |
| SYMBOL | IF0 |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | INFLARX N.V. EO 0,12 |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | US Dollar |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | 147.29 Mil. |
| MARKET CAPITALISATION | 236.26 Mil. |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | -8.24 % | 4.22 % | 11.00 % | 89.49 % | 121.85 % | -57.34 % | -30.32 % | 90.95 % |
| HIGH | 1.80 | 2.17 | 2.43 | 2.43 | 2.43 | 3.92 | 6.31 | 2.43 |
| LOW | 1.57 | 1.54 | 1.20 | 0.65 | 0.65 | 0.62 | 0.62 | 0.65 |
Dividende
pro Aktie
INFLARX N.V. EO 0,12 does not deliver dividend information
Company profile
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. The company was founded by Niels Christoph Riedemann, Renfeng Guo, and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.
Structured products for InflaRX N.V.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
(in 15 days)
08/06/26Q2 2026 Earnings Release
(in 246 days)
03/25/27Q4 2026 Earnings Release
(in 294 days)
05/12/27Q1 2027 Earnings Release
(in 658 days)
05/10/28Q1 2028 Earnings Release